Inhibrx Biosciences stock gains institutional support as Bank of America invests

{
  "signal_id": "b31812cd-3dca-2652-2e50-a4f5758506e5",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-09-20T15:07:27+00:00",
  "company": {
    "name": "Bank of America",
    "domain": "bankofamerica.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/inhibrx-biosciences-stock-gains-institutional-support-as-bank-of-america/70138375",
    "title": "Inhibrx Biosciences stock gains institutional support as Bank of America invests - AD HOC NEWS",
    "excerpt": "Inhibrx Biosciences stock (ISIN US45720L1070) is trading at USD 109.35 on Nasdaq as of September 19, 2026, after attracting fresh institutional interest from Bank of America Corp DE with a disclosed USD 79.70 million investment in the company in September 2026, according to MarketBeat . According to MarketBeat on September 20, 2026, Bank of America Corp DE reported a new position in Inhibrx Biosciences valued at USD 79.70 million, underlining growing institutional confidence in the biotech group. A separate filing reported by MarketBeat on September 20, 2026, shows that Tidal Investments LLC bought 10,170 shares of Inhibrx Biosciences, adding another institutional buyer to the shareholder base. Based on data cited by MarketBeat in September 2026, Inhibrx Biosciences carries an average analyst rating of Moderate Buy and an average price target of USD 197.50, suggesting roughly 80.7 percent upside versus the USD 109.35 Nasdaq price as of September 19, 2026. The same consensus data highlighted by MarketBeat indicate that several covering analysts expect the company to advance its pipeline of biologic therapies, though the stock still reflects the risks typical of clinical-stage biotechnology, including trial outcomes and regulatory decisions. On Nasdaq, Inhibrx Biosciences stock opened at USD 109.35 on September 19, 2026, per price data referenced in the MarketBeat filing...",
    "summary": "Bank of America invested $79.70 million to establish a new position in Inhibrx Biosciences.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2405009_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-09-20T15:07:27Z",
    "effective_date": "2026-09-20",
    "article_sentence": "According to MarketBeat on September 20, 2026, Bank of America Corp DE reported a new position in Inhibrx Biosciences valued at USD 79.70 million, underlining growing institutional confidence in the biotech group.",
    "amount_normalized": 79700000,
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Inhibrx Biosciences",
    "related_company_domain": "inhibrx.com"
  }
}

curl https://signals.autobound.ai/v1/signals/b31812cd-3dca-2652-2e50-a4f5758506e5 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bankofamerica.com","limit":20}'